Dechert Advises NAMSA on Strategic Acquisition of WuXi AppTec’s U.S. Medical Device Testing Operations

Dechert advised NAMSA, a world-leading MedTech testing, clinical and regulatory consulting firm, on a definitive agreement to acquire the U.S. medical device testing operations of China-based WuXi AppTec.

WuXi AppTec is a global company that provides a broad portfolio of R&D and manufacturing services to enable the pharmaceutical and life science industries to advance discoveries and deliver groundbreaking treatments to patients. Under the agreement, NAMSA will acquire WuXi AppTec facilities in Minnesota and Georgia.

NAMSA, an ARCHIMED company acquired by the healthcare-focused global private equity firm in 2020, has made its ninth acquisition since joining ARCHIMED with the purchase of WuXi AppTec’s U.S. Medical Device Testing Operations.

The MedTech industry faces increasingly stringent regulatory and clinical evidence requirements, which can delay development, increase costs and slow market entry. NAMSA's strategic outsourcing and comprehensive in-house services help MedTech innovators mitigate risk, shorten time to market and enhance stakeholder value.

The Dechert team that advised NAMSA included corporate partners Michael S. Darby and Alain Decombe, along with special counsel John M. Ix and Francois Quintard-Morenas and associates Rodrigo A. Rivera, Callie Maslowsky, Christopher Mayer, Remington Shepard and Devyn Kurpis; global tax partner Kevin Zaragoza and associate Ishani Kundu; employee benefits and executive compensation partner Kevin Kay and associate Brie Michaelson; national security partner Jeremy B. Zucker and associate Amy A. Jicha; labor and employment partner J. Ian Downes and associate Julia Canzoneri; intellectual property partner Thomas A. Rayski and associate Frank I. Hwang; and cybersecurity, privacy and AI partner Hilary Bonaccorsi, senior counsel Timothy C. Blank and associate James Smith.

About Dechert

Dechert is a global law firm that advises asset managers, financial institutions and corporations on issues critical to managing their business and their capital – from high-stakes litigation to complex transactions and regulatory matters. We answer questions that seem unsolvable, develop deal structures that are new to the market and protect clients' rights in extreme situations. Our nearly 1,000 lawyers across 19 offices globally focus on the financial services, private equity, private credit, real estate, life sciences and technology sectors.